Full Press Release Details
Results of Annual General Meeting
London: Monday, April 27, 2020: Hutchison China MediTech Limited ( Chi-Med ) (Nasdaq/AIM: HCM) today announces that all ordinary resolutions and special resolutions put to its Annual General Meeting ( AGM ) held on April 27, 2020 were duly passed. The poll results of the resolutions were as follows:
| Number of Votes (%)* | ||||||
| Resolutions | For | Against | Withheld # | |||
| 1 | To consider and adopt the audited financial statements and the reports of the directors and independent auditor for the year ended 31 December 2019. | 622,475,006 (99.97825%) | 135,425 (0.02175%) | 209,095 | ||
| 2(A) | To re-elect Mr Simon To as a director. | 547,656,413 (93.79515%) | 36,229,215 (6.20485%) | 38,935,898 | ||
| 2(B) | To re-elect Mr Christian Hogg as a director. | 614,200,226 (98.61822%) | 8,605,840 (1.38178%) | 15,460 | ||
| 2(C) | To re-elect Mr Johnny Cheng as a director. | 612,394,636 (98.32808%) | 10,412,825 (1.67192%) | 14,065 | ||
| 2(D) | To re-elect Dr Weiguo Su as a director. | 612,400,256 (98.32849%) | 10,410,325 (1.67151%) | 10,945 | ||
| 2(E) | To re-elect Dr Dan Eldar as a director. | 612,014,066 (98.26647%) | 10,796,615 (1.73353%) | 10,845 | ||
| 2(F) | To re-elect Ms Edith Shih as a director. | 612,006,786 (98.26611%) | 10,798,775 (1.73389%) | 15,965 | ||
| 2(G) | To re-elect Mr Paul Carter as a director. | 620,440,741 (99.61989%) | 2,367,325 (0.38011%) | 13,460 | ||
| 2(H) | To re-elect Dr Karen Ferrante as a director. | 622,577,316 (99.96253%) | 233,365 (0.03747%) | 10,845 | ||
| 2(I) | To re-elect Mr Graeme Jack as a director. | 619,884,406 (99.53097%) | 2,921,135 (0.46903%) | 15,985 | ||
| 2(J) | To re-elect Professor Tony Mok as a director. | 622,805,231 (99.99912%) | 5,450 (0.00088%) | 10,845 | ||
| 3 | To re-appoint PricewaterhouseCoopers as the auditor of the Company and authorise the board of directors to fix the auditor's remuneration. | 622,682,786 (99.97980%) | 125,795 (0.02020%) | 12,945 | ||
| 4 | Ordinary Resolution No. 4(A) | : | To grant a general mandate to the directors of the Company to issue additional shares. | 615,116,216 (98.76581%) | 7,686,590 (1.23419%) | 18,720 |
| Special Resolution No. 4(B) | : | To disapply pre-emption rights (general power). | 618,134,451 (99.25233%) | 4,656,435 (0.74767%) | 30,640 | |
| Special Resolution No. 4(C) | : | To disapply pre-emption rights (in connection with an equity raise). | 529,841,459 (86.65474%) | 81,598,207 (13.34526%) | 11,381,860 | |
| Ordinary Resolution No. 4(D) | : | To grant a general mandate to the directors of the Company to repurchase shares of the Company. | 622,786,026 (99.99584%) | 25,890 (0.00416%) | 9,610 | |
| 5 | Ordinary Resolution | : | To amend the 2015 Share Option Scheme and refresh the scheme mandate limit under the 2015 Share Option Scheme. | 501,381,220 (85.77268%) | 83,165,305 (14.22732%) | 38,275,001 |
| 6 | Special Resolution | : | To adopt a new memorandum and articles of association of the Company. | 622,545,861 (99.96014%) | 248,265 (0.03986%) | 27,400 |
* Percentages rounded to 5 decimal places
# A vote withheld is not a vote in law and is not counted in the calculation of the proportion of the votes for and against a resolution.
As at the date of the AGM, the number of issued shares of Chi-Med was 690,574,765, which was the total number of shares entitling the holders to attend and vote on the ordinary resolutions and special resolutions proposed at the AGM.
Chi-Med (Nasdaq/AIM: HCM) is an innovative biopharmaceutical company committed, over the past twenty years, to the discovery and global development of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. It has a portfolio of eight cancer drug candidates currently in clinical studies around the world and extensive commercial infrastructure in its home market of China. For more information, please visit: www.chi-med.com.
| Investor Enquiries | |
| Mark Lee, Senior Vice President | +852 2121 8200 |
| Annie Cheng, Vice President | +1 (973) 567 3786 |
| Media Enquiries | |
| Americas Brad Miles, Solebury Trout | +1 (917) 570 7340 (Mobile) bmiles@troutgroup.com |
| Europe Ben Atwell / Alex Shaw, FTI Consulting | +44 20 3727 1030 / +44 7771 913 902 (Mobile) / +44 7779 545 055 (Mobile) Chi-Med@fticonsulting.com |
| Asia Joseph Chi Lo / Zhou Yi, Brunswick | +852 9850 5033 (Mobile), jlo@brunswickgroup.com / +852 9783 6894 (Mobile), yzhou@brunswickgroup.com |
| Nominated Advisor | |
| Freddy Crossley / Atholl Tweedie, Panmure Gordon (UK) Limited | +44 (20) 7886 2500 |